Baroreflex Activation Therapy

Barostim is an option to improve exercise capacity in the 72% of patients not indicated for CRT

GDMT improves heart failure mortality and morbidity in HFrEF patients, but only shows modest improvement in exercise capacity.¹

a bar graph and a pie graph demonstrating that barostim's baroreflex activation therapy improves exercise capacity in the 72% of patients not indicated for CRT

Barostim rebalances the autonomic nervous system

Barostim’s Baroreflex Activation Therapy works by electrically stimulating carotid baroreceptors which increases baroreflex sensitivity, rebalances the autonomic nervous system and improves heart failure symptoms.

Watch the animation

thumbnail of the barostim mechanism of action video

Baroreflex Activation Therapy is delivered by the Barostim NEO, an implantable pulse generator (IPG) designed to deliver continuous electrical stimulation to carotid baroreceptors.

The Barostim System comprises the Barostim NEO IPG, the Carotid Sinus Lead and a simple, intuitive Programmer.

x-ray illustration of barostim's baroreflex activation therapy device located inside body

Safe implant procedure

The Barostim System is implanted in a safe surgical procedure where the Carotid Sinus Lead is sutured to the carotid sinus and the Barostim NEO IPG is inserted in a standard device pocket.

Procedures are typically performed on an outpatient basis.

The system contains no hardware in the heart or vasculature.

Rebalance the autonomic nervous system. Improve heart failure symptoms.

Barostim is an option to improve exercise capacity in the 72% of patients not indicated for CRT

Barostim rebalances the autonomic nervous system